{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T19:12:02Z","timestamp":1790881922508,"version":"4.1.0"},"reference-count":133,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2021,2,16]],"date-time":"2021-02-16T00:00:00Z","timestamp":1613433600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SPP 2084"],"award-info":[{"award-number":["SPP 2084"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Osteoporosis is characterized by reduced bone mass and disruption of bone architecture, resulting in increased risk of fragility fractures and significant long-term disability. Although both anti-resorptive treatments and osteoanabolic drugs, such as parathyroid hormone analogues, are effective in fracture prevention, limitations exist due to lack of compliance or contraindications to these drugs. Thus, there is a need for novel potent therapies, especially for patients at high fracture risk. Romosozumab is a monoclonal antibody against sclerostin with a dual mode of action. It enhances bone formation and simultaneously suppresses bone resorption, resulting in a large anabolic window. In this opinion-based narrative review, we highlight the role of sclerostin as a critical regulator of bone mass and present human diseases of sclerostin deficiency as well as preclinical models of genetically modified sclerostin expression, which led to the development of anti-sclerostin antibodies. We review clinical studies of romosozumab in terms of bone mass accrual and anti-fracture activity in the setting of postmenopausal and male osteoporosis, present sequential treatment regimens, and discuss its safety profile and possible limitations in its use. Moreover, an outlook comprising future translational applications of anti-sclerostin antibodies in diseases other than osteoporosis is given, highlighting the clinical significance and future scopes of Wnt signaling in these settings.<\/jats:p>","DOI":"10.3390\/jcm10040787","type":"journal-article","created":{"date-parts":[[2021,2,16]],"date-time":"2021-02-16T08:09:09Z","timestamp":1613462949000},"page":"787","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":72,"title":["Osteoporosis Treatment with Anti-Sclerostin Antibodies\u2014Mechanisms of Action and Clinical Application"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4067-6799","authenticated-orcid":false,"given":"Martina","family":"Rauner","sequence":"first","affiliation":[{"name":"Divisions of Endocrinology and Molecular Bone Biology, Department of Medicine III, Medical Center, Technische Universit\u00e4t Dresden, 01307 Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8254-9333","authenticated-orcid":false,"given":"Hanna","family":"Taipaleenm\u00e4ki","sequence":"additional","affiliation":[{"name":"Molecular Skeletal Biology Laboratory, Department of Trauma and Orthopedic Surgery, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Tsourdi","sequence":"additional","affiliation":[{"name":"Divisions of Endocrinology and Molecular Bone Biology, Department of Medicine III, Medical Center, Technische Universit\u00e4t Dresden, 01307 Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0119-1588","authenticated-orcid":false,"given":"Elizabeth M.","family":"Winter","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Center for Bone Quality, Department of Medicine, Leiden University Medical Center, 2300 RC Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,2,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"(2001). NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy, 7\u201329 March 2000: Highlights of the conference. South Med. J., 94, 569\u2013573.","DOI":"10.1097\/00007611-200106000-00005"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/nrendo.2013.179","article-title":"The role of estrogen and androgen receptors in bone health and disease","volume":"9","author":"Manolagas","year":"2013","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1007\/s11657-013-0136-1","article-title":"Osteoporosis in the European Union: Medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA)","volume":"8","author":"Hernlund","year":"2013","journal-title":"Arch. Osteoporos."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1001\/jama.285.3.320","article-title":"Risk of new vertebral fracture in the year following a fracture","volume":"285","author":"Lindsay","year":"2001","journal-title":"JAMA"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"165","DOI":"10.23736\/S0391-1977.20.03137-5","article-title":"Suboptimal medication adherence may favor the progression of vertebral fractures in women with post-menopausal osteoporosis treated with denosumab","volume":"45","author":"Betella","year":"2020","journal-title":"Minerva Endocrinol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1007\/s40618-017-0701-3","article-title":"Persistence with denosumab therapy in women affected by osteoporosis with fragility fractures: A multicenter observational real practice study in Italy","volume":"40","author":"Migliaccio","year":"2017","journal-title":"J. Endocrinol. Investig."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/bonekey.2013.215","article-title":"Coupling the activities of bone formation and resorption: A multitude of signals within the basic multicellular unit","volume":"3","author":"Sims","year":"2014","journal-title":"Bonekey Rep."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"6267","DOI":"10.1093\/emboj\/cdg599","article-title":"Osteocyte control of bone formation via sclerostin, a novel BMP antagonist","volume":"22","author":"Winkler","year":"2003","journal-title":"EMBO J."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"14092","DOI":"10.1073\/pnas.1207188109","article-title":"Targeted deletion of Sost distal enhancer increases bone formation and bone mass","volume":"109","author":"Colette","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1016\/j.str.2011.07.005","article-title":"Wnt antagonists bind through a short peptide to the first beta-propeller domain of LRP5\/6","volume":"19","author":"Bourhis","year":"2011","journal-title":"Structure"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1359\/jbmr.060810","article-title":"Bone density ligand, Sclerostin, directly interacts with LRP5 but not LRP5G171V to modulate Wnt activity","volume":"21","author":"Ellies","year":"2006","journal-title":"J. Bone Miner. Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"26770","DOI":"10.1074\/jbc.M504308200","article-title":"SOST is a ligand for LRP5\/LRP6 and a Wnt signaling inhibitor","volume":"280","author":"Semenov","year":"2005","journal-title":"J. Biol. Chem."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"19489","DOI":"10.1074\/jbc.M110.190330","article-title":"Bone overgrowth-associated mutations in the LRP4 gene impair sclerostin facilitator function","volume":"286","author":"Leupin","year":"2011","journal-title":"J. Biol. Chem."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1074\/jbc.M400524200","article-title":"Sclerostin inhibition of Wnt-3a-induced C3H10T1\/2 cell differentiation is indirect and mediated by bone morphogenetic proteins","volume":"280","author":"Winkler","year":"2005","journal-title":"J. Biol Chem"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"41614","DOI":"10.1074\/jbc.M110.153890","article-title":"Distinct modes of inhibition by sclerostin on bone morphogenetic protein and Wnt signaling pathways","volume":"285","author":"Krause","year":"2010","journal-title":"J. Biol. Chem."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.bone.2004.05.023","article-title":"Sclerostin promotes the apoptosis of human osteoblastic cells: A novel regulation of bone formation","volume":"35","author":"Sutherland","year":"2004","journal-title":"Bone"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Wijenayaka, A.R., Kogawa, M., Lim, H.P., Bonewald, L.F., Findlay, D.M., and Atkins, G.J. (2011). Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0025900"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"6199","DOI":"10.1073\/pnas.1221255110","article-title":"Sclerostin alters serum vitamin D metabolite and fibroblast growth factor 23 concentrations and the urinary excretion of calcium","volume":"110","author":"Ryan","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"11505","DOI":"10.1038\/ncomms11505","article-title":"A bispecific antibody targeting sclerostin and DKK-1 promotes bone mass accrual and fracture repair","volume":"7","author":"Florio","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.bone.2015.12.013","article-title":"Time-dependent cellular and transcriptional changes in the osteoblast lineage associated with sclerostin antibody treatment in ovariectomized rats","volume":"84","author":"Taylor","year":"2016","journal-title":"Bone"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1002\/jbmr.2845","article-title":"Sclerostin expression in bile ducts of patients with chronic cholestasis may influence the bone disease in primary biliary cirrhosis","volume":"31","author":"Gifre","year":"2016","journal-title":"J. Bone Miner. Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"E11238","DOI":"10.1073\/pnas.1707876115","article-title":"Sclerostin influences body composition by regulating catabolic and anabolic metabolism in adipocytes","volume":"114","author":"Kim","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1002\/art.37802","article-title":"Sclerostin is expressed in articular cartilage but loss or inhibition does not affect cartilage remodeling during aging or following mechanical injury","volume":"65","author":"Roudier","year":"2013","journal-title":"Arthritis Rheum."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1002\/dvdy.21054","article-title":"SOST expression is restricted to the great arteries during embryonic and neonatal cardiovascular development","volume":"236","author":"Deruiter","year":"2007","journal-title":"Dev. Dyn."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Zhu, D., Mackenzie, N.C., Millan, J.L., Farquharson, C., and MacRae, V.E. (2011). The appearance and modulation of osteocyte marker expression during calcification of vascular smooth muscle cells. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0019595"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ydbio.2013.08.015","article-title":"Sost and its paralog Sostdc1 coordinate digit number in a Gli3-dependent manner","volume":"383","author":"Colette","year":"2013","journal-title":"Dev. Biol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"13849","DOI":"10.1074\/jbc.M306249200","article-title":"Cbfa1\/RUNX2 directs specific expression of the sclerosteosis gene (SOST)","volume":"279","author":"Sevetson","year":"2004","journal-title":"J. Biol. Chem."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.bbrc.2010.08.128","article-title":"Sclerostin is a direct target of osteoblast-specific transcription factor osterix","volume":"400","author":"Yang","year":"2010","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.mce.2013.02.002","article-title":"Role of BMPs in the regulation of sclerostin as revealed by an epigenetic modifier of human bone cells","volume":"369","author":"Arozamena","year":"2013","journal-title":"Mol. Cell Endocrinol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.bone.2016.01.024","article-title":"Successful induction of sclerostin in human-derived fibroblasts by 4 transcription factors and its regulation by parathyroid hormone, hypoxia, and prostaglandin E2","volume":"85","author":"Fujiwara","year":"2016","journal-title":"Bone"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1359\/jbmr.090806","article-title":"Wnt inhibitors Dkk1 and Sost are downstream targets of BMP signaling through the type IA receptor (BMPRIA) in osteoblasts","volume":"25","author":"Kamiya","year":"2010","journal-title":"J. Bone Miner. Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.bone.2016.10.009","article-title":"Transcriptional control of Sost in bone","volume":"96","author":"Sebastian","year":"2017","journal-title":"Bone"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1359\/jbmr.090730","article-title":"Parathyroid hormone (PTH)-induced bone gain is blunted in SOST overexpressing and deficient mice","volume":"25","author":"Kramer","year":"2010","journal-title":"J. Bone Miner. Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"5866","DOI":"10.1074\/jbc.M705092200","article-title":"Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost\/sclerostin","volume":"283","author":"Robling","year":"2008","journal-title":"J. Biol. Chem."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1359\/jbmr.090411","article-title":"Sclerostin mediates bone response to mechanical unloading through antagonizing Wnt\/beta-catenin signaling","volume":"24","author":"Lin","year":"2009","journal-title":"J. Bone Miner. Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.bone.2011.10.025","article-title":"Sost downregulation and local Wnt signaling are required for the osteogenic response to mechanical loading","volume":"50","author":"Tu","year":"2012","journal-title":"Bone"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.bone.2011.11.016","article-title":"TGF-beta regulates sclerostin expression via the ECR5 enhancer","volume":"50","author":"Loots","year":"2012","journal-title":"Bone"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Nguyen, J., Tang, S.Y., Nguyen, D., and Alliston, T. (2013). Load regulates bone formation and sclerostin expression through a TGFbeta-dependent mechanism. PLoS ONE.","DOI":"10.1371\/journal.pone.0053813"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.bone.2005.03.018","article-title":"SOST is a target gene for PTH in bone","volume":"37","author":"Keller","year":"2005","journal-title":"Bone"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.joca.2011.04.014","article-title":"Increased chondrocyte sclerostin may protect against cartilage degradation in osteoarthritis","volume":"19","author":"Chan","year":"2011","journal-title":"Osteoarthritis Cartil."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1007\/s00223-016-0116-8","article-title":"Systemic inflammation affects human osteocyte-specific protein and cytokine expression","volume":"98","author":"Pathak","year":"2016","journal-title":"Calcif. Tissue Int."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.bbrc.2012.06.100","article-title":"TNF-alpha mediates the stimulation of sclerostin expression in an estrogen-deficient condition","volume":"424","author":"Kim","year":"2012","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1359\/jbmr.090305","article-title":"Pro-inflammatory cytokines TNF-related weak inducer of apoptosis (TWEAK) and TNFalpha induce the mitogen-activated protein kinase (MAPK)-dependent expression of sclerostin in human osteoblasts","volume":"24","author":"Vincent","year":"2009","journal-title":"J. Bone Miner. Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1136\/annrheumdis-2013-203345","article-title":"Sclerostin inhibition reverses systemic, periarticular and local bone loss in arthritis","volume":"72","author":"Chen","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1002\/jcb.22559","article-title":"Hypoxia decreases sclerostin expression and increases Wnt signaling in osteoblasts","volume":"110","author":"Genetos","year":"2010","journal-title":"J. Cell Biochem."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1038\/s41467-018-04679-7","article-title":"Osteocytic oxygen sensing controls bone mass through epigenetic regulation of sclerostin","volume":"9","author":"Stegen","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1136\/jmg.39.2.91","article-title":"Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease","volume":"39","author":"Balemans","year":"2002","journal-title":"J. Med. Genet."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1086\/318811","article-title":"Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein","volume":"68","author":"Brunkow","year":"2001","journal-title":"Am. J. Hum. Genet."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.bone.2016.10.010","article-title":"Sclerostin deficiency in humans","volume":"96","author":"Papapoulos","year":"2017","journal-title":"Bone"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1359\/jbmr.080216","article-title":"Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength","volume":"23","author":"Li","year":"2008","journal-title":"J. Bone Miner. Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1002\/jbmr.2259","article-title":"Sclerostin deficiency is linked to altered bone composition","volume":"29","author":"Hassler","year":"2014","journal-title":"J. Bone Miner. Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1101\/gr.3437105","article-title":"Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease","volume":"15","author":"Loots","year":"2005","journal-title":"Genome Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1002\/ajp.20715","article-title":"Skeletal health: Primate model of postmenopausal osteoporosis","volume":"71","author":"Smith","year":"2009","journal-title":"Am. J. Primatol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1359\/jbmr.081206","article-title":"Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis","volume":"24","author":"Li","year":"2009","journal-title":"J. Bone Miner. Res."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.1002\/jbmr.182","article-title":"Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male rats","volume":"25","author":"Li","year":"2010","journal-title":"J. Bone Miner. Res."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"4785","DOI":"10.1210\/en.2013-1905","article-title":"Progressive increases in bone mass and bone strength in an ovariectomized rat model of osteoporosis after 26 weeks of treatment with a sclerostin antibody","volume":"155","author":"Li","year":"2014","journal-title":"Endocrinology"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1210\/en.2011-0252","article-title":"Increased bone formation and bone mass induced by sclerostin antibody is not affected by pretreatment or cotreatment with alendronate in osteopenic, ovariectomized rats","volume":"152","author":"Li","year":"2011","journal-title":"Endocrinology"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1002\/jbmr.14","article-title":"Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength","volume":"25","author":"Ominsky","year":"2010","journal-title":"J. Bone Miner. Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1002\/jbmr.3036","article-title":"Romosozumab improves bone mass and strength while maintaining bone quality in ovariectomized cynomolgus monkeys","volume":"32","author":"Ominsky","year":"2017","journal-title":"J. Bone Miner. Res."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.bone.2017.04.005","article-title":"Kinetic reconstruction reveals time-dependent effects of romosozumab on bone formation and osteoblast function in vertebral cancellous and cortical bone in cynomolgus monkeys","volume":"101","author":"Boyce","year":"2017","journal-title":"Bone"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s00223-017-0258-3","article-title":"Romosozumab treatment converts trabecular rods into trabecular plates in male cynomolgus monkeys","volume":"101","author":"Matheny","year":"2017","journal-title":"Calcif. Tissue Int."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1002\/jbmr.2092","article-title":"Single- and multiple-dose randomized studies of blosozumab, a monoclonal antibody against sclerostin, in healthy postmenopausal women","volume":"29","author":"McColm","year":"2014","journal-title":"J. Bone Miner. Res."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1002\/jbmr.2351","article-title":"A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density","volume":"30","author":"Recker","year":"2015","journal-title":"J. Bone Miner. Res."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1002\/jbmr.2489","article-title":"The effect of discontinuing treatment with blosozumab: Follow-up results of a phase 2 randomized clinical trial in postmenopausal women with low bone mineral density","volume":"30","author":"Recknor","year":"2015","journal-title":"J. Bone Miner. Res."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/jbmr.173","article-title":"Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody","volume":"26","author":"Padhi","year":"2011","journal-title":"J. Bone Miner. Res."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1002\/jcph.239","article-title":"Multiple doses of sclerostin antibody romosozumab in healthy men and postmenopausal women with low bone mass: A randomized, double-blind, placebo-controlled study","volume":"54","author":"Padhi","year":"2014","journal-title":"J. Clin. Pharmacol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1056\/NEJMoa1305224","article-title":"Romosozumab in postmenopausal women with low bone mineral density","volume":"370","author":"McClung","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.bone.2017.07.005","article-title":"Romosozumab increases bone mineral density in postmenopausal Japanese women with osteoporosis: A phase 2 study","volume":"103","author":"Ishibashi","year":"2017","journal-title":"Bone"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis","volume":"375","author":"Cosman","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.afos.2017.01.002","article-title":"Denosumab for the treatment of osteoporosis","volume":"3","author":"McClung","year":"2017","journal-title":"Osteoporos. Sarcopenia"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or alendronate for fracture prevention in women with osteoporosis","volume":"377","author":"Saag","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1210\/jc.2017-02163","article-title":"A Phase III randomized placebo-controlled trial to evaluate efficacy and safety of romosozumab in men with osteoporosis","volume":"103","author":"Lewiecki","year":"2018","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Golds, G., Houdek, D., and Arnason, T. (2017). Male hypogonadism and osteoporosis: The effects, clinical consequences, and treatment of testosterone deficiency in bone health. Int. J. Endocrinol., 4602129.","DOI":"10.1155\/2017\/4602129"},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Liu, X.X., Jiang, L., Liu, Q., Zhang, J., Niu, W., Liu, J., and Zhang, Q. (2020). Low bone turnover markers in young and middle-aged male patients with type 2 diabetes mellitus. J. Diabetes Res., 6191468.","DOI":"10.1155\/2020\/6191468"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1530\/EJE-17-0417","article-title":"Primary aldosteronism as a cause of secondary osteoporosis","volume":"177","author":"Salcuni","year":"2017","journal-title":"Eur. J. Endocrinol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/S0140-6736(17)31613-6","article-title":"Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: A randomised, open-label, phase 3 trial","volume":"390","author":"Langdahl","year":"2017","journal-title":"Lancet"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1210\/jc.2014-1041","article-title":"Teriparatide increases strength of the peripheral skeleton in premenopausal women with idiopathic osteoporosis: A pilot HR-pQCT study","volume":"99","author":"Nishiyama","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1002\/jbmr.3439","article-title":"Romosozumab FRAME study: A post hoc analysis of the role of regional background fracture risk on nonvertebral fracture outcome","volume":"33","author":"Cosman","year":"2018","journal-title":"J. Bone Miner. Res."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s11657-019-0608-z","article-title":"Increased bone mineral density for 1 year of romosozumab, vs placebo, followed by 2 years of denosumab in the Japanese subgroup of the pivotal FRAME trial and extension","volume":"14","author":"Miyauchi","year":"2019","journal-title":"Arch. Osteoporos."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s00198-020-05324-0","article-title":"Romosozumab or alendronate for fracture prevention in East Asian patients: A subanalysis of the phase III, randomized ARCH study","volume":"31","author":"Lau","year":"2020","journal-title":"Osteoporos. Int."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"e10211","DOI":"10.1002\/jbm4.10211","article-title":"The effect of 1 year of romosozumab on the incidence of clinical vertebral fractures in postmenopausal women with osteoporosis: Results from the FRAME study","volume":"3","author":"Geusens","year":"2019","journal-title":"JBMR Plus"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","article-title":"10 years of denosumab treatment in postmenopausal women with osteoporosis: Results from the phase 3 randomised FREEDOM trial and open-label extension","volume":"5","author":"Bone","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1002\/jbmr.3427","article-title":"FRAME Study: The foundation effect of building bone with 1 year of romosozumab leads to continued lower fracture risk after transition to denosumab","volume":"33","author":"Cosman","year":"2018","journal-title":"J. Bone Miner. Res."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1002\/jbmr.3996","article-title":"T-Score as an indicator of fracture risk during treatment with romosozumab or alendronate in the ARCH trial","volume":"35","author":"Cosman","year":"2020","journal-title":"J. Bone Miner. Res."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.bone.2015.07.036","article-title":"Administration of romosozumab improves vertebral trabecular and cortical bone as assessed with quantitative computed tomography and finite element analysis","volume":"81","author":"Graeff","year":"2015","journal-title":"Bone"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1002\/jbmr.3176","article-title":"Greater gains in spine and hip strength for romosozumab compared with teriparatide in postmenopausal women with low bone mass","volume":"32","author":"Keaveny","year":"2017","journal-title":"J. Bone Miner. Res."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/jbmr.2932","article-title":"Effects of romosozumab compared with teriparatide on bone density and mass at the spine and hip in postmenopausal women with low bone mass","volume":"32","author":"Genant","year":"2017","journal-title":"J. Bone Miner. Res."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1002\/jbmr.3735","article-title":"Bone-forming and antiresorptive effects of romosozumab in postmenopausal women with osteoporosis: Bone histomorphometry and microcomputed tomography analysis after 2 and 12 months of treatment","volume":"34","author":"Chavassieux","year":"2019","journal-title":"J. Bone Miner. Res."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1007\/s00774-019-01057-1","article-title":"Relationship between P1NP, a biochemical marker of bone turnover, and bone mineral density in patients transitioned from alendronate to romosozumab or teriparatide: A post hoc analysis of the STRUCTURE trial","volume":"38","author":"Takada","year":"2020","journal-title":"J. Bone Miner. Metab."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/jbmr.3622","article-title":"One year of romosozumab followed by two years of denosumab maintains fracture risk reductions: Results of the FRAME extension study","volume":"34","author":"Lewiecki","year":"2019","journal-title":"J. Bone Miner. Res."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1002\/jbmr.3452","article-title":"Effects of 24 months of treatment with romosozumab followed by 12 months of denosumab or placebo in postmenopausal women with low bone mineral density: A randomized, double-blind, Phase 2, parallel group study","volume":"33","author":"McClung","year":"2018","journal-title":"J. Bone Miner. Res."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1007\/s00198-019-05146-9","article-title":"Bone mineral density gains with a second 12-month course of romosozumab therapy following placebo or denosumab","volume":"30","author":"Kendler","year":"2019","journal-title":"Osteoporos. Int."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1007\/s00198-020-05502-0","article-title":"A single dose of zoledronate preserves bone mineral density for up to 2 years after a second course of romosozumab","volume":"31","author":"McClung","year":"2020","journal-title":"Osteoporos. Int."},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Migliorini, F., Colarossi, G., Baroncini, A., Eschweiler, J., Tingart, M., and Maffulli, N. (2020). Pharmacological management of postmenopausal osteoporosis: A level I evidence based expert opinion. Exp. Rev. Clin. Pharmacol.","DOI":"10.1080\/17512433.2021.1851192"},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Wen, F., Du, H., Ding, L., Hu, J., Huang, Z., Huang, H., Li, K., Mo, Y., and Kuang, A. (2020). Clinical efficacy and safety of drug interventions for primary and secondary prevention of osteoporotic fractures in postmenopausal women: Network meta-analysis followed by factor and cluster analysis. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0234123"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1007\/s00198-019-05183-4","article-title":"Osteoporosis drugs for prevention of clinical fracture in white postmenopausal women: A network meta-analysis of survival data","volume":"31","author":"Ding","year":"2020","journal-title":"Osteoporos. Int."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.maturitas.2019.08.003","article-title":"Comparative efficacy of bone anabolic therapies in women with postmenopausal osteoporosis: A systematic review and network meta-analysis of randomized controlled trials","volume":"129","author":"Hernandez","year":"2019","journal-title":"Maturitas"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.afos.2020.02.003","article-title":"Risk of falls in postmenopausal women treated with romosozumab: Preliminary indices from a meta-analysis of randomized, controlled trials","volume":"6","author":"Bartneck","year":"2020","journal-title":"Osteoporos Sarcopenia"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"3261","DOI":"10.1007\/s10067-020-04948-1","article-title":"Efficacy and safety of Romosozumab in treatment for low bone mineral density: A systematic review and meta-analysis","volume":"39","author":"Kaveh","year":"2020","journal-title":"Clin. Rheumatol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"115121","DOI":"10.1016\/j.bone.2019.115121","article-title":"Denosumab or romosozumab therapy and risk of cardiovascular events in patients with primary osteoporosis: Systematic review and meta- analysis","volume":"130","author":"Lv","year":"2020","journal-title":"Bone"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1007\/s00198-020-05379-z","article-title":"Explanations for the difference in rates of cardiovascular events in a trial of alendronate and romosozumab","volume":"31","author":"Cummings","year":"2020","journal-title":"Osteoporos. Int."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/jbmr.3581","article-title":"Clinically relevant doses of sclerostin antibody do not induce osteonecrosis of the jaw (ONJ) in rats with experimental periodontitis","volume":"34","author":"Hadaya","year":"2019","journal-title":"J. Bone Miner. Res."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1002\/jbmr.4001","article-title":"Serious adverse events with romosozumab use in Japanese patients: Need for clear formulation of contraindications worldwide","volume":"35","author":"Kawaguchi","year":"2020","journal-title":"J. Bone Miner. Res."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1089\/mab.2019.0049","article-title":"Safety of romosozumab in osteoporotic men and postmenopausal women: A meta-analysis and systematic review","volume":"39","author":"Mariscal","year":"2020","journal-title":"Monoclon. Antib. Immunodiagn. Immunother."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.bone.2019.04.011","article-title":"Sclerostin antibody reduces long bone fractures in the oim\/oim model of osteogenesis imperfecta","volume":"124","author":"Cardinal","year":"2019","journal-title":"Bone"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.bone.2014.10.012","article-title":"Rapidly growing Brtl\/+ mouse model of osteogenesis imperfecta improves bone mass and strength with sclerostin antibody treatment","volume":"71","author":"Sinder","year":"2015","journal-title":"Bone"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1007\/s00198-014-2737-y","article-title":"Adult Brtl\/+ mouse model of osteogenesis imperfecta demonstrates anabolic response to sclerostin antibody treatment with increased bone mass and strength","volume":"25","author":"Sinder","year":"2014","journal-title":"Osteoporos. Int."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1007\/s00223-019-00655-5","article-title":"Sclerostin-antibody treatment decreases fracture rates in axial skeleton and improves the skeletal phenotype in growing oim\/oim mice","volume":"106","author":"Cardinal","year":"2020","journal-title":"Calcif. Tissue Int."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.bone.2014.06.015","article-title":"Effect of sclerostin antibody treatment in a mouse model of severe osteogenesis imperfecta","volume":"66","author":"Roschger","year":"2014","journal-title":"Bone"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1002\/jbmr.3143","article-title":"BPS804 anti-sclerostin antibody in adults with moderate osteogenesis imperfecta: Results of a randomized Phase 2a trial","volume":"32","author":"Glorieux","year":"2017","journal-title":"J. Bone Miner. Res."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.bone.2016.09.013","article-title":"Single dose of bisphosphonate preserves gains in bone mass following cessation of sclerostin antibody in Brtl\/+ osteogenesis imperfecta model","volume":"93","author":"Perosky","year":"2016","journal-title":"Bone"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1002\/jbmr.3421","article-title":"Low dose of bisphosphonate enhances sclerostin antibody-induced trabecular bone mass gains in Brtl\/+ osteogenesis imperfecta mouse model","volume":"33","author":"Olvera","year":"2018","journal-title":"J. Bone Miner. Res."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.bone.2017.04.016","article-title":"Combination sclerostin antibody and zoledronic acid treatment outperforms either treatment alone in a mouse model of osteogenesis imperfecta","volume":"101","author":"Little","year":"2017","journal-title":"Bone"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1002\/jbmr.3923","article-title":"Sclerostin antibody treatment increases bone mass and normalizes circulating phosphate levels in growing Hyp mice","volume":"35","author":"Carpenter","year":"2020","journal-title":"J. Bone Miner. Res."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.matbio.2015.12.009","article-title":"Sclerostin antibody (Scl-Ab) improves osteomalacia phenotype in dentin matrix protein 1(Dmp1) knockout mice with little impact on serum levels of phosphorus and FGF23","volume":"52\u201354","author":"Ren","year":"2016","journal-title":"Matrix Biol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1182\/blood-2017-03-773341","article-title":"Inhibiting the osteocyte-specific protein sclerostin increases bone mass and fracture resistance in multiple myeloma","volume":"129","author":"McDonald","year":"2017","journal-title":"Blood"},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Hesse, E., Schr\u00f6der, S., Brandt, D., Pamperin, J., Saito, H., and Taipaleenm\u00e4ki, H. (2019). Sclerostin inhibition alleviates breast cancer-induced bone metastases and muscle weakness. JCI Insight, 5.","DOI":"10.1172\/jci.insight.125543"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.coph.2016.02.007","article-title":"Bone pain: Current and future treatments","volume":"28","author":"Frost","year":"2016","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_119","doi-asserted-by":"crossref","unstructured":"Harris, S.E., Rediske, M., Neitzke, R., and Rakian, A. (2017). Periodontal biology: Stem cells, Bmp2 gene, transcriptional enhancers, and use of sclerostin antibody and PTH for treatment of periodontal disease and bone loss. Cell Stem Cells Regen. Med., 3.","DOI":"10.16966\/2472-6990.113"},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Hassan, M.G., Zaher, A.R., Palomo, J.M., and Palomo, L. (2018). Sclerostin modulation holds promise for dental indications. Healthcare, 6.","DOI":"10.3390\/healthcare6040134"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1002\/jbmr.1984","article-title":"Sclerostin antibody stimulates bone regeneration after experimental periodontitis","volume":"28","author":"Taut","year":"2013","journal-title":"J. Bone Miner. Res."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1172\/JCI83731","article-title":"Efficacy of anti-sclerostin monoclonal antibody BPS804 in adult patients with hypophosphatasia","volume":"127","author":"Seefried","year":"2017","journal-title":"J. Clin. Investig."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"211ra158","DOI":"10.1126\/scitranslmed.3006627","article-title":"Sclerostin inhibition reverses skeletal fragility in an Lrp5-deficient mouse model of OPPG syndrome","volume":"5","author":"Kedlaya","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/jbmr.2372","article-title":"Anti-sclerostin antibody treatment in a rat model of progressive renal osteodystrophy","volume":"30","author":"Moe","year":"2015","journal-title":"J. Bone Miner. Res."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.bone.2015.04.021","article-title":"Compromised vertebral structural and mechanical properties associated with progressive kidney disease and the effects of traditional pharmacological interventions","volume":"77","author":"Newman","year":"2015","journal-title":"Bone"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1002\/art.30385","article-title":"Sclerostin antibody treatment enhances bone strength but does not prevent growth retardation in young mice treated with dexamethasone","volume":"63","author":"Marenzana","year":"2011","journal-title":"Arthritis Rheum."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"R125","DOI":"10.1186\/ar4305","article-title":"Effect of sclerostin-neutralising antibody on periarticular and systemic bone in a murine model of rheumatoid arthritis: A microCT study","volume":"15","author":"Marenzana","year":"2013","journal-title":"Arthritis Res. Ther."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"330ra35","DOI":"10.1126\/scitranslmed.aac4351","article-title":"Sclerostin inhibition promotes TNF-dependent inflammatory joint destruction","volume":"8","author":"Wehmeyer","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.lssr.2017.01.001","article-title":"Sclerostin antibody inhibits skeletal deterioration in mice exposed to partial weight-bearing","volume":"12","author":"Spatz","year":"2017","journal-title":"Life Sci. Space Res."},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Phillips, E.G., Beggs, L.A., Ye, F., Conover, C.F., Beck, D.T., Otzel, D.M., Ghosh, P., Bassit, A.C.F., Borst, S.E., and Yarrow, J.F. (2018). Effects of pharmacologic sclerostin inhibition or testosterone administration on soleus muscle atrophy in rodents after spinal cord injury. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0194440"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.bone.2017.07.015","article-title":"Patients with non-ambulatory cerebral palsy have higher sclerostin levels and lower bone mineral density than patients with ambulatory cerebral palsy","volume":"103","author":"Shin","year":"2017","journal-title":"Bone"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"693","DOI":"10.2106\/JBJS.19.00790","article-title":"A randomized, placebo-controlled study of romosozumab for the treatment of hip fractures","volume":"15","author":"Schemitsch","year":"2020","journal-title":"J. Bone Jt. Surg. Am."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.2106\/JBJS.19.01008","article-title":"Romosozumab in skeletally mature adults with a fresh unilateral tibial diaphyseal fracture: A randomized phase-2 study","volume":"102","author":"Bhandari","year":"2020","journal-title":"J. Bone Jt. Surg. Am."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/4\/787\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:24:43Z","timestamp":1760160283000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/4\/787"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,16]]},"references-count":133,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,2]]}},"alternative-id":["jcm10040787"],"URL":"https:\/\/doi.org\/10.3390\/jcm10040787","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,16]]}}}